公开(公告)号：US07541363B2

公开(公告)日：2009-06-02

申请号：US10554511

申请日：2004-05-07

申请人： Kazutoshi Kuroda ,  Noboru Aoki ,  Toshiro Ochiai ,  Akihiro Uchida ,  Yasuhiro Ishikawa ,  Makoto Kigoshi ,  Eiji Hayakawa ,  Kazuki Asanome

发明人： Kazutoshi Kuroda ,  Noboru Aoki ,  Toshiro Ochiai ,  Akihiro Uchida ,  Yasuhiro Ishikawa ,  Makoto Kigoshi ,  Eiji Hayakawa ,  Kazuki Asanome

IPC分类号： C07D473/06 ,  A61K31/522

CPC分类号： C07D473/06

摘要： Microcrystals of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione having an average particle size of less than 50 μm; microcrystals of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione having an average particle size of less than 50 μm and a crystallinity of 20% or more or the like, which possess excellent solubility, stability, bioavailability, dispersing property in a pharmaceutical formulation; and the like are provided. A solid pharmaceutical formulation which is characterized by comprising the same is also provided.

摘要翻译： 平均粒径小于50埃的（E）-8-（3,4-二甲氧基苯乙烯基）-1,3-二乙基-7-甲基-3,7-二氢-1H-嘌呤-2,6-二酮的微晶 妈妈 （E）-8-（3,4-二甲氧基苯乙烯基）-1,3-二乙基-7-甲基-3,7-二氢-1H-嘌呤-2,6-二酮的微晶，平均粒径小于50 具有优异的溶解性，稳定性，生物利用度，药物配方中的分散性的20％以上的结晶度等。 等等。 还提供了其特征在于包含其的固体药物制剂。